1 min read
Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody
Pandion will leverage Selexis’ proprietary technology platform to advance an antibody targeting autoimmune and inflammatory diseases
Admin
.png?width=1800&height=600&name=MicrosoftTeams-image%20(82).png)
2 min read
Selexis and Boston Immune Technologies and Therapeutics (BITT) Enter Service Agreement to Advance BITT’s Lead TNFR2 Oncology Candidate
Admin: Mar 9, 2021 12:00:00 AM
Geneva, Switzerland, and Boston, Mass., March 9, 2021 – Selexis SA and Boston Immune Technologies and Therapeutics (BITT) have entered into a service…
2 min read
Igyxos and Selexis Enter Service Agreement to Advance Igyxos’ First-In-Class Monoclonal Antibody for the Treatment of Human Infertility
Admin: Sep 2, 2020 12:00:00 AM
Geneva, Switzerland, and Nouzilly, France, September 2, 2020 – Selexis SA and Igyxos announced today that they have entered into a service agreement…
2 min read
Selexis Expands Scientific and Operational Leadership Teams with Key Promotions
Admin: May 19, 2020 12:00:00 AM
Geneva, Switzerland, May 19, 2020 – Selexis SA, a JSR Life Sciences Company, today announced key promotions across its scientific and operational…
2 min read
Teneobio and Selexis Expand Relationship with Three Commercial License Agreements for Multi-specific Antibody Candidates in Oncology
Admin: Oct 17, 2019 12:00:00 AM
Geneva, Switzerland, and Newark, CA, OCTOBER 17, 2019 – Selexis SA and Teneobio, Inc. announced today that they have signed three commercial license…
2 min read
Generium Launches First Biosimilar of Dornase Alfa; Becomes Sixth Approved Product Using Selexis SUREtechnology Platform
Admin: Sep 17, 2019 12:00:00 AM
Geneva, Switzerland, and Moscow, Russia, September 17, 2019 – Selexis SA and Generium JSC today announced that a sixth Selexis SUREtechnology…
3 min read
Avacta and Selexis Partner to Develop Cell Line for Clinical Manufacturing
Admin: Jun 20, 2019 12:00:00 AM
Avacta’s first Affimer clinical candidate is a potent PD-L1 antagonist under development for solid tumour indications as the basis of bispecific and…
3 min read
Generium Launches First Biosimilar of Eculizumab; Becomes Fifth Marketed Product Using Selexis SUREtechnology Platform
Admin: Apr 9, 2019 12:00:00 AM
Geneva, Switzerland, and Moscow, Russia, April 9, 2019 – Selexis SA and Generium JSC today announced that a fifth Selexis SUREtechnology…
2 min read
Selexis SA and Turgut Pharmaceuticals Expand Biosimilar Development Relationship by Signing Two Commercial License Agreements
Admin: Feb 26, 2019 12:00:00 AM
Under the New CLAs, Selexis Will Help Advance Turgut’s Pipeline of Biosimilar Products in Oncology
2 min read
Selexis Expands Strategic Immuno-Oncology Alliance with Agenus
Admin: Jan 9, 2019 12:00:00 AM
Agenus to Leverage Selexis’ SUREtechnology Platform™ to Progress its Unique Portfolio of Next-Generation Antibody Programs Through the Clinic